Kolexia
Peyrade Frederic Oncologie hémato.
Peyrade Frederic
Oncologie hémato.
Centre Antoine Lacassagne
Nice, France
235 Activités
496 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Carcinome épidermoïde Carcinomes Lymphome B diffus à grandes cellules Lymphome B Tumeurs de la tête et du cou Carcinome épidermoïde de la tête et du cou Récidive tumorale locale Maladie de Hodgkin

Collaborateurs

Voir plus
Poissonnet Gilles
Poissonnet Gilles
Centre Antoine Lacassagne, Nice, France
Chamorey Emmanuel
Chamorey Emmanuel
Centre Antoine Lacassagne, Nice, France
Bozec Alexandre
Bozec Alexandre
Centre Antoine Lacassagne, Nice, France
Dassonville Olivier
Dassonville Olivier
Cabinet libéral, Cagnes-sur-Mer, France

Industries

Voir plus
BMS
10 collaboration(s)
Dernière en 2021
Merck-Serono
4 collaboration(s)
Dernière en 2021
MSD
4 collaboration(s)
Dernière en 2021
KEPHREN
2 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer: A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
Essai Clinique (BMS)   02 janvier 2024
Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study
65th ASH Annual Meeting Late-Breaking Abstracts   21 novembre 2023
Synthetic Control Arm from Clinical Trials and Real-World Data from Lysa Group for Untreated Diffuse Large B Cell Lymphoma Patients Aged over 80 Years: A Bona Fide Strategy for Innovative Clinical Trials
65th ASH Annual Meeting Abstracts   02 novembre 2023
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO): Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma
Essai Clinique (Pharmacyclics LLC.)   26 septembre 2023
TRANSCRIPT: Transplantation After Complete Response In Patients With T-cell Lymphoma
Essai Clinique (Hospices Civils de Lyon)   26 septembre 2023
VITALIZE: A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Essai Clinique (ImmunoVaccine Technologies, Inc. (IMV Inc.))   05 avril 2023
Liens entre vaccins anti-Covid et cancer : "Nous, cancérologues ...
L'Express   18 mars 2023
Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older: Phase II, Open-Label Study Evaluating Efficacy of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older
Essai Clinique (The Lymphoma Academic Research Organisation)   16 mars 2023
Relyage: Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
Essai Clinique (CHU Amiens-Picardie)   07 février 2023